Results 81 to 90 of about 7,838 (234)

Comparison of Insulin Lispro Protamine Suspension with NPH Insulin in Pregnant Women with Type 2 and Gestational Diabetes Mellitus: Maternal and Perinatal Outcomes

open access: yesInternational Journal of Endocrinology, 2013
Insulin therapy is still the gold standard in diabetic pregnancy. Insulin lispro protamine suspension is an available basal insulin analogue. Aim. To study pregnancy outcomes of women with type 2 and gestational diabetes mellitus when insulin lispro ...
Antonietta Colatrella   +5 more
doaj   +1 more source

ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes

open access: yesDiabetes, obesity and metabolism, 2020
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
G. Andersen   +11 more
semanticscholar   +1 more source

Prevalence of Vitamin D Deficiency and Its Association With PTH and Type 1 Diabetes Mellitus (T1DM) in a Multicultural Pediatric Population in the United Arab Emirates, 2023

open access: yesJournal of Diabetes, Volume 18, Issue 9, September 2026.
This cross‐sectional study conducted in the United Arab Emirates investigated Vitamin D status in 102 pediatric patients (ages 3–18) with Type 1 Diabetes Mellitus in the United Arab Emirates, revealing a high prevalence of Vitamin D insufficiency that frequently presents alongside normal parathyroid hormone levels.
Mariam K. Ibrahim   +4 more
wiley   +1 more source

How the First 9 Months Shape the Rest of Your Life: The Impact of Gestational Diabetes on the Metabolic Future

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7705-7718, September 2026.
ABSTRACT Gestational diabetes mellitus (GDM) represents far more than a transient glycaemic disorder: it is a sentinel metabolic event that unveils pre‐existing defects in β‐cell function and insulin action, with profound implications for both maternal and offspring cardiometabolic health across the lifespan.
Mustafa Kanat   +2 more
wiley   +1 more source

Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus

open access: yes, 2016
Aims: To compare metabolic control under lispro and recombinant regular human insulin (RHI) in people with diet-unresponsive type 2 diabetes mellitus (T2DM) and compensated non-alcoholic liver disease (CLD).
Guarino, G.   +10 more
core   +1 more source

Use of Insulin Lispro Protamine Suspension in Pregnancy [PDF]

open access: yes, 2015
Maternal metabolism changes substantially during pregnancy, which poses numerous challenges to physicians managing pregnancy in women with diabetes. Insulin is the agent of choice for glycemic control in pregnant women with diabetes, and the insulin ...
Paolo Moghetti   +9 more
core   +1 more source

Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes [PDF]

open access: yes, 2004
Objective. The optimal approach to relatively recent onset type 2 diabetes patients is still unknown. We speculated that the use of short-acting insulin analogs might be of particular benefit in this context. Patients and Methods.
Yagi, Kunimasa   +6 more
core   +2 more sources

Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro (URLi) vs Lispro (Humalog®) Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.

open access: yesClinical Therapeutics, 2020
PURPOSE Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control.
J. Leohr   +7 more
semanticscholar   +1 more source

One Week Exposure to a Somatostatin Receptor 2 Antagonist (SSTR2a) Enhances Glucagon Counterregulation to Insulin‐Induced Hypoglycaemia and Does Not Worsen Glycemia in a Male Rat Model of Insulin‐Requiring Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8208-8218, September 2026.
ABSTRACT Introduction Administration of a somatostatin receptor 2 antagonist (SSTR2a) increases glucagon responsiveness to hypoglycaemia in insulin‐treated type 2 diabetes (T2D), but the durability of this effect and the impact of repeated SSTR2a dosing on overall glycaemia in T2D are unclear.
Ninoschka C. D'Souza   +7 more
wiley   +1 more source

Atenção farmacêutica ao paciente diabético tipo 1 em uso de insulina [PDF]

open access: yes, 2014
Trabalho apresentado no 31º SEURS - Seminário de Extensão Universitária da Região Sul, realizado em Florianópolis, SC, no período de 04 a 07 de agosto de 2013 - Universidade Federal de Santa Catarina.O diabetes mellitus (DM) é uma doença caracterizada ...
Daher, Josélia, Garabeli, Aline
core  

Home - About - Disclaimer - Privacy